[Form 4] Kyverna Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kyverna Therapeutics Executive Chairperson Shaw Christi reported new equity awards from the company. On January 12, 2026, Shaw Christi received 30,000 shares of common stock as a restricted stock unit award, which vests in four equal annual installments starting January 12, 2027, subject to continued service.

She also received 24,301 performance restricted stock units that vest only if Kyverna’s common stock reaches specified share price targets. In addition, she was granted a stock option for 185,000 shares of common stock at an exercise price of $8.23 per share, with one quarter vesting on January 12, 2027 and the remainder vesting monthly thereafter, conditioned on continued service. Following these awards, she beneficially owned 70,935 shares of common stock and 185,000 stock options directly.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Shaw Christi

Role Executive Chairperson

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	185,000	$0.00	--
Grant/Award	Common Stock	30,000	$0.00	--
Grant/Award	Common Stock	24,301	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 185,000 shares (Direct); Common Stock — 46,634 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit award of common stock, 1/4th of the shares subject to which shall vest on January 12, 2027, and 1/4th of the shares subject to the restricted stock unit award shall vest following each one-year period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Represents a performance restricted stock unit award of common stock, which will vest upon the Issuer's common stock achieving certain specified prices per share. 1/4th of the shares subject to the option shall vest on January 12, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shaw Christi

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairperson

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		A		30,000(1)	A	$0	46,634	D
Common Stock	01/12/2026		A		24,301(2)	A	$0	70,935	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.23	01/12/2026		A		185,000		(3)	01/11/2036	Common Stock	185,000	$0.00	185,000	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock, 1/4th of the shares subject to which shall vest on January 12, 2027, and 1/4th of the shares subject to the restricted stock unit award shall vest following each one-year period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. Represents a performance restricted stock unit award of common stock, which will vest upon the Issuer's common stock achieving certain specified prices per share.

3. 1/4th of the shares subject to the option shall vest on January 12, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

	By: /s/ Samantha Eldredge, as Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.